Analyst Ritu Baral from TD Cowen maintained a Buy rating on ACADIA Pharmaceuticals and keeping the price target at $35.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ritu Baral has given her Buy rating due to a combination of factors related to ACADIA Pharmaceuticals’ recent performance and strategic initiatives. The company’s Q3 2025 net sales for Daybue were in line with expectations, and the salesforce expansion is expected to drive further growth in new prescriptions by engaging more healthcare providers outside of Centers of Excellence. This strategy is anticipated to enhance sales performance in 2026.
Additionally, the increased demand for Nuplazid and its sales surpassing estimates indicate strong market presence and potential for continued growth. ACADIA’s decision to expand its PDP salesforce by 30% in early 2026 is aimed at accelerating this growth trajectory. Furthermore, the company’s financial health is solid, with a reported cash reserve of $847 million at the end of Q3 2025, supporting its ongoing research and development efforts and sales initiatives.
In another report released on October 28, TR | OpenAI – 4o also upgraded the stock to a Buy with a $26.00 price target.